<DOC>
	<DOCNO>NCT00637455</DOCNO>
	<brief_summary>To compare effect fexofenadine HCl 180 mg , cetirizine 10 mg , placebo computerized score derive Aeromedical Vigilance Task ( AVT ) , computerize objective measure attention , accuracy reaction time healthy naval flight personnel . Specifically , primary objective compare AVT overall ( average 18 block ) mean change baseline total number error ( commission error + omission error ) fexofenadine HCl cetirizine 10 mg. Safety single-dose treatment also assess .</brief_summary>
	<brief_title>Single Center , Randomized , Double-Blind , Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg , Cetirizine 10 mg , Placebo Cognitive Performance Naval Flight Personnel</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Male female naval flight personnel , â‰¥18 year age CogScreenAE Logistic Regression Probability Value &lt; 0.6 baseline screen visit Normal SaO2 ( &gt; 95 % ) measure pulse oximetry Female subject must nonchildbearing potential ( i.e. , surgically sterile least 1 year postmenopausal ) ; see Section 4.4 additional information : Female subject pregnant , lactating , likely become pregnant study Signs symptom currently active allergic disease ( seasonal allergic rhinitis , perennial allergic rhinitis , episodic allergic rhinitis ) within 2 week prior screen visit Upper respiratory tract infection , sinusitis , asthma exacerbation , flulike symptom within 2 week prior screen visit Medical history physical examination finding ; clinically significant cardiovascular , respiratory , hepatic , neurologic , endocrine , psychiatric , major systemic disease ; laboratory electrocardiograph abnormality make implementation protocol interpretation protocol result difficult . Abnormalities clinically significant necessarily disqualify subject provide , opinion investigator sponsor , study validity subject 's welfare compromise . Any unusual sleep pattern , include thirdshift worker ( 11:00 PM 7:00 AM ) , sleep &lt; 6 hour night AVT test Visits 14 Any excessive amount alcohol ( two drinks/day average ) Any excessive use caffeine ( three cup coffee per day equivalent ) Any history chronic alcohol moodaltering drug abuse Any use tobacco/nicotine product within 90 day screen visit study Any disease state surgery know affect gastrointestinal absorption drug Mental capacity limit extent subject give legal inform consent accurate information regard efficacy side effects/tolerance drug Subjects unable comply protocol requirement ( must complete screen visit Visits 14 within approximately 11/2 month ) Known hypersensitivity fexofenadine , tablet ingredient ( croscarmellose sodium , magnesium stearate , microcrystalline cellulose , pregelatinized starch ; tablet coating make hydroxypropyl methylcellulose , iron oxide blend , polyethylene glycol , povidone , silicone dioxide , titanium dioxide ) Known hypersensitivity cetirizine tablet ingredient ( lactose , magnesium stearate , povidone , titanium dioxide , hydroxypropyl methylcellulose , polyethylene glycol , corn starch ) Use investigational drug within 30 day prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>